Literature DB >> 16096519

Dependence on zolpidem: two case reports of detoxification with flumazenil infusion.

GianLuca Quaglio1, Fabio Lugoboni, Anna Fornasiero, Alessandro Lechi, Gilberto Gerra, Paolo Mezzelani.   

Abstract

Zolpidem is a hypnotic drug that is chemically distinct from benzodiazepines (BDZ). It has been suggested that it acts selectively on gamma-aminobutyric acid receptors. However, recent evidence has shown that the behavioural effects of zolpidem are generally similar to those of BDZs. Flumazenil is usually considered to be a BDZ antagonist. Nonetheless, in chronic BDZ users, it acts as a partial, bland agonist. We describe two cases of zolpidem dependence that were detoxified by the use of flumazenil infusion. BDZ dependence is usually treated with tapering of the medication. As an alternative, abrupt discontinuation of the medication and rapid detoxification using flumazenil has been used. Flumazenil may represent an alternative to detoxification treatment by employing a tapering approach, or by replacement therapy with BDZs with a long half-life, particularly where patients are hard to treat or have low compliance to treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096519     DOI: 10.1097/01.yic.0000166404.41850.b4

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

1.  Exploring the dark side of the moon: the treatment of benzodiazepine tolerance.

Authors:  Fabio Lugoboni; Gianluca Quaglio
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 2.  Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2008-01-12       Impact factor: 3.533

3.  Pharmacoepidemiological characterisation of zolpidem and zopiclone usage.

Authors:  Caroline Victorri-Vigneau; F Feuillet; L Wainstein; M Grall-Bronnec; J Pivette; A Chaslerie; V Sébille; P Jolliet
Journal:  Eur J Clin Pharmacol       Date:  2013-07-23       Impact factor: 2.953

4.  Determinants of Quality of Life in High-Dose Benzodiazepine Misusers.

Authors:  Stefano Tamburin; Angela Federico; Marco Faccini; Rebecca Casari; Laura Morbioli; Valentina Sartore; Antonio Mirijello; Giovanni Addolorato; Fabio Lugoboni
Journal:  Int J Environ Res Public Health       Date:  2017-01-04       Impact factor: 3.390

5.  'Z-trip'? A Comprehensive Overview and a Case-series of Zolpidem Misuse.

Authors:  Laura Orsolini; Stefania Chiappini; Paolo Grandinetti; Angelo Bruschi; Roberta Testa; Alessandra Provenzano; Domenico De Berardis; Umberto Volpe
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

6.  Addiction of High Dose of Benzodiazepine: Verona Detox Approach With Flumazenil.

Authors:  Rebecca Casari; Antonio Metastasio; Lorenzo Zamboni; Martino Biasioli; Simone Campagnari; Fabio Lugoboni
Journal:  Front Psychiatry       Date:  2022-03-31       Impact factor: 4.157

7.  Lormetazepam addiction: data analysis from an Italian medical unit for addiction.

Authors:  Marco Faccini; Roberto Leone; Benedetta Pajusco; Gianluca Quaglio; Rebecca Casari; Anna Albiero; Monia Donati; Fabio Lugoboni
Journal:  Risk Manag Healthc Policy       Date:  2012-06-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.